Company Description
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders.
The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression.
It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression.
The company was founded in 2014 and is headquartered in Baltimore, Maryland.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Dr. Christopher C. Chapman Jr., M.D. |
Contact Details
Address: 855 N. Wolfe Street, Suite 601 Baltimore, Maryland 21205 United States | |
| Phone | 856-848-8698 |
| Website | mymd.com |
Stock Details
| Ticker Symbol | MYMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001321834 |
| CUSIP Number | 00973E409 |
| ISIN Number | US62856X2018 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher C. Chapman Jr., M.D. | President, Chief Medical Officer and Director |
| Ian Rhodes CPA | Interim Chief Financial Officer |
| Dr. Adam Kaplin M.D., Ph.D. | Chief Scientific Officer |
| Dr. Jenna Brager M.S., Ph.D., R.N. | Executive Vice President of Drug Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | 8-K | Current Report |
| Apr 8, 2024 | 8-K | Current Report |
| Apr 1, 2024 | 10-K | Annual Report |
| Mar 26, 2024 | 8-K/A | [Amend] Current report |
| Mar 7, 2024 | 8-K | Current Report |
| Mar 5, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | 8-K | Current Report |
| Dec 6, 2023 | 8-K | Current Report |